Skip to main content

Table 2 MO-Mediated and Antibody-Dependent Cellular Cytotoxicity of Untreated MOs from EOC Patients and Normal Subjects

From: Cytokines, GM-CSF and IFNγ administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin

 

EOC Patients

Normal Donor Samples*

 

MO antibody treatment

No.

Mean ± SD

No.

Mean ± SD

P Value

None

8

0.8 ± 1.9

4

3.4 ± 3.2

.04

2B6 antibody

6

1.0 ± 2.3

4

8.5 ± 5.0

.02

trastuzumab

8

2.5 ± 3.1

5

11.5 ± 11.1

.06

trastuzumab + 2B6 antibody

6

4.1 ± 4.4

6

9.9 ± 5.9

.11

  1. All experiments run with a concurrent control from 3 cryopreserved donor samples (see Methods).
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us